90 related articles for article (PubMed ID: 18647846)
1. Human breast cancer tumor models: molecular imaging of drug susceptibility and dosing during HER2/neu-targeted therapy.
Gee MS; Upadhyay R; Bergquist H; Alencar H; Reynolds F; Maricevich M; Weissleder R; Josephson L; Mahmood U
Radiology; 2008 Sep; 248(3):925-35. PubMed ID: 18647846
[TBL] [Abstract][Full Text] [Related]
2. Fe
Yin Q; Gao X; Zhang H; Zhang Z; Yu X; He J; Shi G; Hao L
Biomed Mater; 2024 Apr; 19(3):. PubMed ID: 38626777
[TBL] [Abstract][Full Text] [Related]
3. In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies.
Koyama Y; Barrett T; Hama Y; Ravizzini G; Choyke PL; Kobayashi H
Neoplasia; 2007 Dec; 9(12):1021-9. PubMed ID: 18084609
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence Lifetime Imaging for Quantification of Targeted Drug Delivery in Varying Tumor Microenvironments.
Verma A; Pandey V; Sherry C; James C; Matteson K; Smith JT; Rudkouskaya A; Intes X; Barroso M
bioRxiv; 2024 Mar; ():. PubMed ID: 38293105
[TBL] [Abstract][Full Text] [Related]
5. Near-infrared dye IRDye800CW-NHS coupled to Trastuzumab for near-infrared II fluorescence imaging in tumor xenograft models of HER-2-positive breast cancer.
Xiao J; Qiu S; Ma Q; Bai S; Guo X; Wang L
J Mater Chem B; 2023 Nov; 11(44):10738-10746. PubMed ID: 37929679
[TBL] [Abstract][Full Text] [Related]
6. Detecting Disruption of HER2 Membrane Protein Organization in Cell Membranes with Nanoscale Precision.
Moradi Y; Lee JSH; Armani AM
ACS Sens; 2024 Jan; 9(1):52-61. PubMed ID: 37955934
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and
Gristwood K; Luli S; Rankin KS; Knight JC
ACS Omega; 2023 Dec; 8(50):47905-47912. PubMed ID: 38144136
[TBL] [Abstract][Full Text] [Related]
8. Fluorescence response of human HER2+ cancer- and MCF-12F normal cells to 200MHz ultrasound microbeam stimulation: a preliminary study of membrane permeability variation.
Hwang JY; Lee J; Lee C; Jakob A; Lemor R; Medina-Kauwe LK; Shung KK
Ultrasonics; 2012 Sep; 52(7):803-8. PubMed ID: 22513260
[TBL] [Abstract][Full Text] [Related]
9. 3D Imaging Detection of HER2 Based in the Use of Novel Affibody-Quantum Dots Probes and Ratiometric Analysis.
Pérez-Treviño P; la Cerda HH; Pérez-Treviño J; Fajardo-Ramírez OR; García N; Altamirano J
Transl Oncol; 2018 Jun; 11(3):672-685. PubMed ID: 29627705
[TBL] [Abstract][Full Text] [Related]
10. Red-Fluorescent Pt Nanoclusters for Detecting and Imaging HER2 in Breast Cancer Cells.
Tanaka SI; Wadati H; Sato K; Yasuda H; Niioka H
ACS Omega; 2020 Sep; 5(37):23718-23723. PubMed ID: 32984690
[TBL] [Abstract][Full Text] [Related]
11. Too Much, Too Little, or Just Right? Obesity and Dosing of Targeted Therapies in Breast Cancer.
Cao C; Ligibel JA
J Clin Oncol; 2023 Nov; 41(33):5090-5092. PubMed ID: 37797274
[No Abstract] [Full Text] [Related]
12. A DM1-doped porous gold nanoshell system for NIR accelerated redox-responsive release and triple modal imaging guided photothermal synergistic chemotherapy.
Xu P; Wang R; Yang W; Liu Y; He D; Ye Z; Chen D; Ding Y; Tu J; Shen Y
J Nanobiotechnology; 2021 Mar; 19(1):77. PubMed ID: 33741008
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models.
Fiordelisi MF; Auletta L; Meomartino L; Basso L; Fatone G; Salvatore M; Mancini M; Greco A
Contrast Media Mol Imaging; 2019; 2019():8946729. PubMed ID: 31598114
[TBL] [Abstract][Full Text] [Related]
14. Influence of chelator and near-infrared dye labeling on biocharacteristics of dual-labeled trastuzumab-based imaging agents.
Wang X; Aldrich MB; Yang Z; Zhou N; Xie Q; Liu C; Sevick-Muraca E
Chin J Cancer Res; 2016 Jun; 28(3):362-9. PubMed ID: 27478322
[TBL] [Abstract][Full Text] [Related]
15. Optical imaging probes in oncology.
Martelli C; Lo Dico A; Diceglie C; Lucignani G; Ottobrini L
Oncotarget; 2016 Jul; 7(30):48753-48787. PubMed ID: 27145373
[TBL] [Abstract][Full Text] [Related]
16. Tumor penetrating peptides for improved drug delivery.
Ruoslahti E
Adv Drug Deliv Rev; 2017 Feb; 110-111():3-12. PubMed ID: 27040947
[TBL] [Abstract][Full Text] [Related]
17. TOPK is highly expressed in circulating tumor cells, enabling metastasis of prostate cancer.
Sun H; Zhang L; Shi C; Hu P; Yan W; Wang Z; Duan Q; Lu F; Qin L; Lu T; Xiao J; Wang Y; Zhu F; Shao C
Oncotarget; 2015 May; 6(14):12392-404. PubMed ID: 25881543
[TBL] [Abstract][Full Text] [Related]
18. Collagen density and alignment in responsive and resistant trastuzumab-treated breast cancer xenografts.
Walsh AJ; Cook RS; Lee JH; Arteaga CL; Skala MC
J Biomed Opt; 2015 Feb; 20(2):26004. PubMed ID: 25700233
[TBL] [Abstract][Full Text] [Related]
19. Antibody-based imaging of HER-2: moving into the clinic.
Wang RE; Zhang Y; Tian L; Cai W; Cai J
Curr Mol Med; 2013 Dec; 13(10):1523-37. PubMed ID: 24206138
[TBL] [Abstract][Full Text] [Related]
20. Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer.
Walsh AJ; Cook RS; Manning HC; Hicks DJ; Lafontant A; Arteaga CL; Skala MC
Cancer Res; 2013 Oct; 73(20):6164-74. PubMed ID: 24130112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
